Bernstein Initiates Regeneron Pharmaceuticals At Outperform

Analysts at Bernstein initiated coverage on

with a Outperform rating. The target price for Regeneron Pharmaceuticals is set to $475. Regeneron Pharmaceuticals shares have gained 20.92% over the past 52 weeks, while the S&P 500 index has surged 13.92% in the same period. Regeneron Pharmaceuticals' shares rose 0.16% to close at $402.40 on Friday.